AR026293A1 - Formas polimorficas de hidrocloruro de sertralina - Google Patents

Formas polimorficas de hidrocloruro de sertralina

Info

Publication number
AR026293A1
AR026293A1 ARP000105711A ARP000105711A AR026293A1 AR 026293 A1 AR026293 A1 AR 026293A1 AR P000105711 A ARP000105711 A AR P000105711A AR P000105711 A ARP000105711 A AR P000105711A AR 026293 A1 AR026293 A1 AR 026293A1
Authority
AR
Argentina
Prior art keywords
sertraline hydrochloride
polymorphic forms
polymorphic
forms
preparation
Prior art date
Application number
ARP000105711A
Other languages
English (en)
Spanish (es)
Original Assignee
Ciba Sc Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8243113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR026293(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Sc Holding Ag filed Critical Ciba Sc Holding Ag
Publication of AR026293A1 publication Critical patent/AR026293A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP000105711A 1999-10-29 2000-10-27 Formas polimorficas de hidrocloruro de sertralina AR026293A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99810981 1999-10-29

Publications (1)

Publication Number Publication Date
AR026293A1 true AR026293A1 (es) 2003-02-05

Family

ID=8243113

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105711A AR026293A1 (es) 1999-10-29 2000-10-27 Formas polimorficas de hidrocloruro de sertralina

Country Status (17)

Country Link
US (2) US6872853B1 (enExample)
EP (1) EP1224160B1 (enExample)
JP (1) JP2003513062A (enExample)
CN (1) CN1384816A (enExample)
AR (1) AR026293A1 (enExample)
AT (1) ATE409684T1 (enExample)
AU (1) AU1386301A (enExample)
CA (1) CA2387135A1 (enExample)
DE (1) DE60040406D1 (enExample)
HU (1) HUP0203559A3 (enExample)
IL (2) IL149050A0 (enExample)
MX (1) MXPA02004255A (enExample)
MY (1) MY141509A (enExample)
TR (1) TR200201146T2 (enExample)
TW (1) TWI260315B (enExample)
WO (1) WO2001032601A1 (enExample)
ZA (1) ZA200203254B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632472A1 (en) * 1998-11-27 2006-03-08 Teva Pharmaceutical Industries Ltd Sertraline hydrochloride polymorphs
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
DE69929462T2 (de) * 1998-11-27 2006-09-07 Teva Pharmaceutical Industries Ltd. Sertralin hydrochlorid form
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
US7442838B2 (en) * 1999-10-29 2008-10-28 Ciba Specialty Chemicals Corp. Polymorphic forms of sertraline hydrochloride
US20050119351A1 (en) * 1999-10-29 2005-06-02 Van Der Schaaf Paul A. Polymorphic forms of sertraline hydrochloride
WO2001045692A1 (en) * 1999-12-21 2001-06-28 Teva Pharmaceutical Industries Ltd. Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
EP1772144A3 (en) * 1999-12-21 2007-08-15 Teva Pharmaceutical Industries Ltd Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
IN192343B (enExample) * 2000-05-26 2004-04-10 Ranbaxy Lab Ltd
CA2448279A1 (en) 2001-05-31 2002-12-05 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
WO2003093217A1 (en) * 2002-04-29 2003-11-13 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
MXPA04011375A (es) * 2002-06-27 2005-02-14 Interdigital Tech Corp Controlador de red de radio para intercambio de informacion de equipo.
WO2005000786A1 (en) 2003-05-23 2005-01-06 Transform Pharmaceuticals, Inc. Sertraline compositions
US7893300B2 (en) 2003-11-04 2011-02-22 Cipla Limited Process for the preparation of polymorphs of selective serotonin reuptake inhibitor
WO2005075467A2 (en) * 2004-02-06 2005-08-18 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
WO2007008317A2 (en) * 2005-06-09 2007-01-18 Teva Pharmaceutical Industries Ltd. Process for preparation of sertraline hydrochloride form i
US7518019B2 (en) 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
US9186642B2 (en) 2010-04-28 2015-11-17 The Procter & Gamble Company Delivery particle
US9993793B2 (en) 2010-04-28 2018-06-12 The Procter & Gamble Company Delivery particles
CN103458871B (zh) 2011-04-07 2015-05-13 宝洁公司 具有增强的聚丙烯酸酯微胶囊的沉积的调理剂组合物
WO2012138710A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Personal cleansing compositions with increased deposition of polyacrylate microcapsules
WO2012138696A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Shampoo compositions with increased deposition of polyacrylate microcapsules
CN105061217A (zh) * 2015-06-30 2015-11-18 徐静 枸橼酸舍曲林的2种晶型及其制备方法
CA3194468A1 (en) 2020-10-16 2022-04-21 Johan Smets Consumer product compositions comprising a population of encapsulates
MX2023004232A (es) 2020-10-16 2023-04-21 Procter & Gamble Composiciones de productos de consumo con al menos dos poblaciones de encapsulados.
US12486478B2 (en) 2020-10-16 2025-12-02 The Procter & Gamble Company Consumer products comprising delivery particles with high core:wall ratios
CN112552188B (zh) * 2020-12-17 2023-07-28 山西仟源医药集团股份有限公司 盐酸舍曲林晶型i的制备方法
CN113588626B (zh) * 2021-08-24 2024-05-24 上海师范大学 一种苯丙氨酸对映体的拉曼光谱检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5082970A (en) 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114947D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5734083A (en) 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
HU222341B1 (hu) 1996-12-18 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
DE69713353D1 (de) * 1997-12-11 2002-07-18 Torcan Chemical Ltd Sertralin-Polymorph mit verbesserter Wasserlöslichkeit
CA2323629A1 (en) 1998-03-18 1999-09-23 Ciba Specialty Chemicals Holding Inc. Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
JP2000026378A (ja) 1998-07-03 2000-01-25 Sumika Fine Chemicals Co Ltd 塩酸セルトラリンの製法
DE69929462T2 (de) 1998-11-27 2006-09-07 Teva Pharmaceutical Industries Ltd. Sertralin hydrochlorid form
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
WO2001045692A1 (en) 1999-12-21 2001-06-28 Teva Pharmaceutical Industries Ltd. Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them

Also Published As

Publication number Publication date
ATE409684T1 (de) 2008-10-15
MY141509A (en) 2010-05-14
ZA200203254B (en) 2003-07-22
TWI260315B (en) 2006-08-21
AU1386301A (en) 2001-05-14
IL149050A0 (en) 2002-11-10
MXPA02004255A (es) 2002-10-17
EP1224160A1 (en) 2002-07-24
US20040132828A1 (en) 2004-07-08
CN1384816A (zh) 2002-12-11
HUP0203559A2 (hu) 2003-03-28
US6939992B2 (en) 2005-09-06
WO2001032601A1 (en) 2001-05-10
US6872853B1 (en) 2005-03-29
JP2003513062A (ja) 2003-04-08
DE60040406D1 (de) 2008-11-13
EP1224160B1 (en) 2008-10-01
IL149050A (en) 2007-03-08
HUP0203559A3 (en) 2008-01-28
TR200201146T2 (tr) 2004-12-21
CA2387135A1 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
AR026293A1 (es) Formas polimorficas de hidrocloruro de sertralina
CO2021016594A2 (es) Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina
ECSP056020A (es) Inhibidores del factor inhibidor de la migración de los macrofagos y metodos para su identificacion
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CO2021010598A2 (es) Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar
AR071788A1 (es) Derivados de 3-aminocarbazol, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos para tratar y/o prevenir trastornos asociados con la produccion de prostaglandina e2(pge2), tales como aterosclerosis, artritis, artrosis y tumores, entre otros.
UY27304A1 (es) Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
IL183244A0 (en) Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
UY26886A1 (es) Polimorfos de un análogo de epotilona
UY26962A1 (es) Monohidrato cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento
CR6616A (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
AR061066A1 (es) Coterapeutica para el tratamiento de epilepsia y trastornos relacionados
CR6436A (es) Inhibidores de la receptacion de monoaminas para el tratamiento de trastornos del snc
UY27169A1 (es) Derivados del ácido isoftálico como inhibidores de metalproteinasas de la matriz
CO6660435A2 (es) Una forma cristalina de clorhidrato de (r) -7- cloro-n- (quinuclidin -3-il)benzo[b] tiofeno-2- carboxamida monohodratado
CL2019003258A1 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos.
AR076519A1 (es) Coaglomerados de manitol y de almidon granular comprimibles y de libre fluidez. procedimiento de preparacion.
BR0212807A (pt) Processo para a preparação de formas de dosagem de dissolução rápida
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
UY27410A1 (es) Formas novedosas crudas cristalinas
UY29320A1 (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, así como preparaciones farmacéuticas que las contienen
AR024494A1 (es) Proceso para la preparacion de derivados de ciclopentano sustituido y novedosas estructuras cristalinas de los mismos
UY25356A1 (es) Polisacaridos de sintesis,procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2582660T3 (es) Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal